

Preclinical Evaluation of a Minimally Invasive Energy-based Device for Localized Nucleic Acid Delivery to Skin

Join us for the next session in Genoskin's webinar series, where we explore how an energy-driven, microneedle-based device enables localized, non-viral delivery of naked nucleic acids to skin, with preclinical in vivo and ex vivo data highlighting transgene expression, immune activation, and current limitations of this approach.

This episode of Genoskin's webinar series is scheduled for:
📅 March 17th, 2026
🕗 8 a.m. (PDT) | 11 a.m. (EDT) | 4 p.m. (CEST)

Register Now:
https://attendee.gotowebinar.com/register/6334858686878209627?source=News+outlets

Preclinical Assessment of an Energy-Based Skin Delivery Device

Discover new approaches to overcoming one of the key bottlenecks in cutaneous gene delivery: achieving efficient, localized nucleic acid delivery without viral vectors or lipid nanoparticles.

Efficient delivery of nucleic acids to skin remains a major challenge for non-viral technologies, limiting their translational potential in vaccines, immunotherapies, and gene-based dermatological applications. In this webinar, Dr. Ria Michalaki, VP of R&D at Piezo Therapeutics, will present preclinical data evaluating an energy-driven, microneedle-based device designed to mechanically enhance delivery of naked nucleic acids to skin. Drawing on results from in vivo animal models and ex vivo skin models, she will demonstrate localized transgene expression and immune activation, while also discussing the current opportunities and limitations of mechanically driven, non-viral delivery strategies.

This webinar is a must-attend for researchers and developers in gene therapy, vaccines, immunology, dermatology, and drug delivery who are seeking clinically relevant, non-viral approaches for skin-targeted nucleic acid delivery.

Register now to gain insight into the future of mechanically driven gene delivery to skin.

Register Now:

https://attendee.gotowebinar.com/register/6334858686878209627?source=News+outlets

About the Speaker:

Dr. Ria Michalaki
Vice President of R&D at Piezo Therapeutics

Dr. Ria Michalaki, PhD, is Vice President of Research and Development at Piezo Therapeutics, where she leads translational research efforts focused on non-viral nucleic acid delivery and device-enabled gene delivery technologies. Her work spans preclinical model development, skin biology, and energy-based delivery platforms. She received her PhD in Chemical Engineering from Stanford University and completed postdoctoral training at the Georgia Institute of Technology.

Additional resource on Dr. Michalaki's research:

A piezoelectric electroporator (Piezopen) for enhanced "naked" RNA vaccine delivery.
Michalaki, E., Van Zanten, A., Najjar, J., & Byagathvalli, G. bioRxiv, 2025. (preprint) doi: https://doi.org/10.1101/2025.02.07.637103